News articles about Endocyte (NASDAQ:ECYT) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endocyte earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.108772854218 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- You Need To Know About Analysts Ratings on: Endocyte, Inc. (ECYT) (nasdaqplace.com)
- Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop? (finance.yahoo.com)
- Why Endocyte Stock Jumped Higher Today (fool.com)
- Endocyte’s radiotherapeutic 177Lu-PSMA-617 shows positive effect in mid-stage prostate cancer study; shares ahead … (seekingalpha.com)
- Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA … (globenewswire.com)
Endocyte stock opened at $13.51 on Friday. The stock has a market capitalization of $841.66 million, a PE ratio of -13.51 and a beta of 0.47. Endocyte has a 12 month low of $12.12 and a 12 month high of $12.72.
A number of analysts have issued reports on the company. Zacks Investment Research lowered Endocyte from a “buy” rating to a “hold” rating in a research note on Friday, May 11th. BidaskClub upgraded Endocyte from a “buy” rating to a “strong-buy” rating in a report on Friday, May 4th. ValuEngine upgraded Endocyte from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Finally, Cowen upgraded Endocyte from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Endocyte has a consensus rating of “Buy” and an average price target of $9.00.
In other news, VP Christopher P. Leamon sold 5,036 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $9.07, for a total value of $45,676.52. Following the transaction, the vice president now directly owns 143,470 shares in the company, valued at approximately $1,301,272.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 14.86% of the company’s stock.
Endocyte Company Profile
Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.